サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1750842

ライブバイオセラピー製品とマイクロバイオームCDMOの市場規模、シェア、動向分析レポート：用途別、地域別、セグメント予測、2025～2030年

Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Trends Analysis Report By Application (C. Difficile, Crohn's Disease, IBS, Diabetes), By Region (North America, Europe, APAC, MEA), And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 137 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
ライブバイオセラピー製品とマイクロバイオームCDMOの市場規模、シェア、動向分析レポート：用途別、地域別、セグメント予測、2025～2030年
出版日: 2025年05月23日
発行: Grand View Research
ページ情報: 英文 137 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ライブバイオセラピー製品とマイクロバイオームCDMO市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のライブバイオセラピー製品とマイクロバイオームCDMOの市場規模は2030年までに3億9,749万米ドルに達し、2025～2030年までのCAGRは38.5%で拡大すると予測されています。市場は近年急速に成長しており、この動向は今後も続くと予想されます。患者やヘルスケアプロバイダーの間で、炎症性腸疾患、がん、神経疾患を含む様々な疾患の治療におけるライブバイオセラピー製品やマイクロバイオームベースの治療薬の潜在的な利点に対する理解が高まっています。

これらの分野に特化したCDMOのニーズは、製薬企業やバイオテクノロジー企業によるライブバイオセラピー製品やマイクロバイオームベースの医薬品への投資の拡大によってもたらされており、この動向は今後10年間も続くと予想されます。LBPやマイクロバイオームベースの治療薬市場の拡大に伴い、企業はこれらの製品の開発・製造に必要なスキルを持つCDMOを求めています。その結果、世界のCDMO市場は成長し、今後数年間で大幅な拡大が見込まれています。

こうした治療法の開発は複雑さを増しているため、CDMOへのアウトソーシングは製薬会社やバイオテクノロジー企業にとって魅力的な選択肢になりつつあります。例えば、臨床段階のバイオ医薬品会社であるExeliom Biosciencesは、2023年7月、EXL01の複数の臨床試験を含む治療パイプラインの臨床開発を進めるため、2,630万米ドルのシリーズA資金調達を発表しました。EXL01は、感染症やがんに応用可能な新規免疫療法薬です。

ライブバイオセラピー製品とマイクロバイオームベースの治療薬には、用途に応じた市場セグメントが設けられており、現在はC.ディフィシルカテゴリーが市場を独占しています。再発性C・ディフィシル感染症という深刻かつ拡大しつつある健康問題に対処するために、効果的な医薬品が切実に必要とされています。例えば、2023年10月、Ferring Pharmaceuticalsは、米国消化器病学会（American College of Gastroenterology）の2023年年次学術集会で、REBYOTAの2つの発表を行ったと報告しました。これは、再発性C.ディフィシル感染症（CDI）に対する抗生物質治療後の18歳以上の成人における再発性C.ディフィシル感染症（CDI）の予防を目的とした、米国FDAによって承認された初めての単回投与マイクロバイオームベースの治療薬です。C.ディフィシルやその他の病気に対する効果的な治療に対するニーズが高まっていることから、ライブバイオセラピー製品やマイクロバイオームベースの医薬品市場は発展すると予想されます。

COVID-19のパンデミックは、ライブバイオセラピー製品とマイクロバイオーム受託開発製造機関（CDMO）の市場に大きな影響を与えました。パンデミックによる混乱は、臨床試験の遅延、特定の製品に対する需要の減少、サプライチェーンの混乱につながりました。しかし、パンデミックに関連する規制が緩和され、ヘルスケアへの注目度が高まっていることから、LBPとマイクロバイオーム治療薬の市場は今後数年で回復すると予想されます。この分野の企業は、パンデミック後の世界で成長を維持するために、新たな課題に適応し、革新的な解決策を見出す必要があると思われます。

ライブバイオセラピー製品とマイクロバイオームCDMO市場レポートハイライト

  • C.ディフィシル感染症の有病率の増加と効果的な治療に対する需要の高まりにより、2024年にはC.ディフィシルが最大の売上シェアを占め、ライブバイオセラピー製品およびマイクロバイオーム受託開発・製造市場の成長を促進しています。
  • 多くの企業がC.ディフィシル感染症を治療するための製品の開発と製造に注力しており、市場の拡大を牽引しています。
  • 北米のライブバイオセラピー製品とマイクロバイオームCDMO市場は、2024年に世界市場の76.84％の最大シェアを占めました。
  • アジア太平洋は予測期間中にCAGR 44.82%で成長すると予想されます。アジア太平洋地域の市場は、近年の著しい成長と有望な動向を目の当たりにしています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ライブバイオセラピー製品とマイクロバイオームCDMO市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助的な市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • テクノロジー情勢
  • 価格モデル分析
  • 2024年の臨床試験件数分析
  • 業界市場分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 ライブバイオセラピー製品とマイクロバイオームCDMO市場：用途別、推定・動向分析

  • セグメントダッシュボード
  • ライブバイオセラピー製品とマイクロバイオームCDMO市場：用途変動分析
  • ライブバイオセラピー製品とマイクロバイオームCDMO市場規模と動向分析：用途別、2018～2030年
  • C.ディフィシル
  • クローン病
  • IBS
  • 糖尿病
  • その他

第5章 ライブバイオセラピー製品とマイクロバイオームCDMO市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域別市場ダッシュボード
  • 市場規模と予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • ノルウェー
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 競合の分類
  • Company Market Assessment Analysis, 2024
  • 企業プロファイル
    • Arrant Bio
    • 4D Pharma
    • Cerbios
    • Biose Industrie
    • Assembly Biosciences, Inc.
    • Wacker Chemie AG
    • Quay Pharmaceuticals
    • NIZO
    • Lonza
    • Inpac Probiotics
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global live biotherapeutic products and microbiome CDMO market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America live biotherapeutic products and microbiome CDMO market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 9 Mexico live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 10 Europe live biotherapeutic products and microbiome CDMO market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 12 UK live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 13 Germany live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 14 France live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 15 Italy live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 16 Spain live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 17 Denmark live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 18 Sweden live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 19 Norway live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific live biotherapeutic products and microbiome CDMO market, by country, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 22 Japan live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 23 China live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 24 India live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 25 Australia live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 26 South Korea live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 27 Thailand live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 28 Latin America live biotherapeutic products and microbiome CDMO market, by country, 2018 - 2030 (USD Million)
  • Table 29 Latin America live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 30 Brazil live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 31 Argentina live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 32 MEA live biotherapeutic products and microbiome CDMO market, by country, 2018 - 2030 (USD Million)
  • Table 33 MEA live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 34 South Africa live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 35 Saudi Arabia live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 36 UAE live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 37 Kuwait live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Live biotherapeutic products and microbiome CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Data analysis models
  • Fig. 5 Market formulation and validation
  • Fig. 6 Data validating & publishing
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Parent market outlook, 2024 (USD Billion)
  • Fig. 12 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 13 Live biotherapeutic products and microbiome CDMO market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Live biotherapeutic products and microbiome CDMO market: PESTEL analysis
  • Fig. 16 Live biotherapeutic products and microbiome CDMO market, by application, 2024 (USD Million)
  • Fig. 17 Companies with affected trials, by size
  • Fig. 18 Affected trials, by study phase
  • Fig. 19 Clinical trial scenario (as of January 2024)
  • Fig. 20 Live biotherapeutic products and microbiome CDMO market: Application outlook and key takeaways
  • Fig. 21 Live biotherapeutic products and microbiome CDMO market: Application movement analysis
  • Fig. 22 C. difficile market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Crohn's disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 IBS market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Regional market: Key takeaways
  • Fig. 28 Regional outlook, 2024 & 2030
  • Fig. 29 Regional outlook, key takeaways
  • Fig. 30 North America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Key country dynamics
  • Fig. 32 U.S. live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Key country dynamics
  • Fig. 34 Canada live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Europe live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 UK live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Germany live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 France live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Italy live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Spain live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Denmark live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Sweden live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Norway live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 China live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Japan live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 India live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Australia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Thailand live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 South Korea live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Brazil live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Mexico live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Argentina live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 MEA live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 South Africa live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Saudi Arabia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 UAE live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Kuwait live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Market participant categorization
  • Fig. 82 Heat map analysis
  • Fig. 83 Market participant categorization
目次
Product Code: GVR-4-68040-061-6

Live Biotherapeutic Products And Microbiome CDMO Market Growth & Trends:

The global live biotherapeutic products and microbiome CDMO market size is expected to reach USD 397.49 million by 2030, expanding at a CAGR of 38.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has been growing quickly in recent years, and this trend is anticipated to continue. The rising understanding of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating various diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers.

The need for CDMOs specializing in these fields is being driven by the expanding investment by pharmaceutical and biotech businesses in live biotherapeutic products and microbiome-based medicines, and this trend is anticipated to continue in the next ten years. Companies are looking for CDMOs with the skills required to develop and produce these products as the market for LBPs and microbiome-based therapeutics grows. This has resulted in the growth of the global CDMO market, with significant expansion expected in the coming years.

Due to the increasing complexity of developing these therapies, outsourcing to CDMOs is becoming an attractive option for pharmaceutical and biotech companies. For instance, in July 2023, Exeliom Biosciences, a clinical-stage biopharmaceutical company, announced a USD 26.30 million Series A funding to advance the clinical development of its therapeutic pipeline, which includes several clinical trials of EXL01. EXL01 is a novel immunotherapy with applications in infectious diseases and cancer.

Applications-based market segments have been created for live biotherapeutic products and microbiome-based therapeutics, with the C. difficile category currently dominating the market. Effective medicines are desperately required to tackle the major and expanding health issue of recurrent C. difficile infection. For instance, in October 2023, Ferring Pharmaceuticals announced two presentations at the American College of Gastroenterology's 2023 Annual Scientific Meeting for REBYOTA. It is the first single-dose microbiome-based treatment approved by the U.S. FDA to prevent recurrent C. difficile Infection (CDI) in adults aged 18 & above following antibiotic treatment for recurrent CDI. The market for live biotherapeutic products and microbiome-based medicines is anticipated to develop since there is an increasing need for effective treatments for C. difficile and other illnesses.

The COVID-19 pandemic has significantly impacted the market for live biotherapeutic products and microbiome contract development and manufacturing organizations (CDMOs). The disruption caused by the pandemic has led to delays in clinical trials, decreased demand for certain products, and supply chain disruptions. However, with the easing of pandemic-related restrictions and the increasing focus on healthcare, the market for LBPs and microbiome-based therapies is expected to rebound in the coming years. Companies in this space will need to adapt to new challenges and find innovative solutions to maintain growth in a post-pandemic world.

Live Biotherapeutic Products And Microbiome CDMO Market Report Highlights:

  • C.difficle held the largest revenue share in 2024 owing to the increasing prevalence of C.difficle infections and the growing demand for effective treatments are propelling the growth of the live biotherapeutic products and microbiome contract development and manufacturing market.
  • Many companies focus on developing and manufacturing products for treating C.difficle infections, driving the market's expansion.
  • North America live biotherapeutic products and microbiome CDMO market accounted for the largest share of 76.84% in 2024 of the global live biotherapeutic products and microbiome market.
  • Asia Pacific is expected to grow at a CAGR of 44.82% during the forecast period. The market in Asia Pacific has witnessed significant growth and promising developments in recent years.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Information Analysis
    • 1.4.2. Market Formulation & Data Visualization
    • 1.4.3. Data Validation & Publishing
  • 1.5. Model Details
    • 1.5.1. Commodity Flow Analysis (Model 1)
    • 1.5.2. Top Down Market Estimation (Model 2)
    • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
    • 1.5.4. Multivariate Analysis (Model 4)
  • 1.6. List of Secondary Sources
  • 1.7. List of Abbreviations
  • 1.8. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Live Biotherapeutic Products And Microbiome CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High Potential of Live Biotherapeutic Products and Microbiome in Treating Chronic & Infectious Diseases
      • 3.2.1.2. Increase in Clinical Research on Live Biotherapeutic Products
      • 3.2.1.3. Increasing Demand for One-Stop-Shop CDMOs
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues in Outsourcing
      • 3.2.2.2. Availability of Substitutes
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trial Volume Analysis, 2024
  • 3.6. Industry Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Live Biotherapeutic Products and Microbiome CDMO Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Live Biotherapeutic Products and Microbiome CDMO Market Application Movement Analysis
  • 4.3. Global Live Biotherapeutic Products and Microbiome CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. C. Difficle
    • 4.4.1. C. Difficle Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Crohn's disease
    • 4.5.1. Crohn's Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. IBS
    • 4.6.1. IBS Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Diabetes
    • 4.7.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmaceutical Transportation Services Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2024 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Market Size & Forecasts Trend Analysis, 2018 to 2030 (USD Million)
  • 5.4. North America
    • 5.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Competitive scenario
      • 5.4.2.3. Regulatory scenario
      • 5.4.2.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Canada
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Competitive scenario
      • 5.4.3.3. Regulatory scenario
      • 5.4.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Mexico
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Competitive scenario
      • 5.4.4.3. Regulatory scenario
      • 5.4.4.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Europe
    • 5.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.5.2. UK
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Competitive scenario
      • 5.5.2.3. Regulatory scenario
      • 5.5.2.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Germany
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Competitive scenario
      • 5.5.3.3. Regulatory scenario
      • 5.5.3.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.4. France
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Competitive scenario
      • 5.5.4.3. Regulatory scenario
      • 5.5.4.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.5. Italy
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Competitive scenario
      • 5.5.5.3. Regulatory scenario
      • 5.5.5.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.6. Spain
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Competitive scenario
      • 5.5.6.3. Regulatory scenario
      • 5.5.6.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.7. Denmark
      • 5.5.7.1. Key country dynamics
      • 5.5.7.2. Competitive scenario
      • 5.5.7.3. Regulatory scenario
      • 5.5.7.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.8. Norway
      • 5.5.8.1. Key country dynamics
      • 5.5.8.2. Competitive scenario
      • 5.5.8.3. Regulatory scenario
      • 5.5.8.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.9. Sweden
      • 5.5.9.1. Key country dynamics
      • 5.5.9.2. Competitive scenario
      • 5.5.9.3. Regulatory scenario
      • 5.5.9.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Asia Pacific
    • 5.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Japan
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Competitive scenario
      • 5.6.2.3. Regulatory scenario
      • 5.6.2.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. China
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Competitive scenario
      • 5.6.3.3. Regulatory scenario
      • 5.6.3.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. India
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Competitive scenario
      • 5.6.4.3. Regulatory scenario
      • 5.6.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.5. Australia
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Competitive scenario
      • 5.6.5.3. Regulatory scenario
      • 5.6.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.6. South Korea
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Competitive scenario
      • 5.6.6.3. Regulatory scenario
      • 5.6.6.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.7. Thailand
      • 5.6.7.1. Key country dynamics
      • 5.6.7.2. Competitive scenario
      • 5.6.7.3. Regulatory scenario
      • 5.6.7.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Latin America
    • 5.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Brazil
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Competitive scenario
      • 5.7.2.3. Regulatory scenario
      • 5.7.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.3. Argentina
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Competitive scenario
      • 5.7.3.3. Regulatory scenario
      • 5.7.3.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8. MEA
    • 5.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.8.2. South Africa
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Competitive scenario
      • 5.8.2.3. Regulatory scenario
      • 5.8.2.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.3. Saudi Arabia
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Competitive scenario
      • 5.8.3.3. Regulatory scenario
      • 5.8.3.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.4. UAE
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Competitive scenario
      • 5.8.4.3. Regulatory scenario
      • 5.8.4.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.5. Kuwait
      • 5.8.5.1. Key country dynamics
      • 5.8.5.2. Competitive scenario
      • 5.8.5.3. Regulatory scenario
      • 5.8.5.4. Israel market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Competition Categorization
  • 6.2. Company Market Assessment Analysis, 2024
  • 6.3. Company Profiles
    • 6.3.1. Arrant Bio
      • 6.3.1.1. Company overview
      • 6.3.1.2. Financial performance
      • 6.3.1.3. Service benchmarking
      • 6.3.1.4. Strategic initiatives
    • 6.3.2. 4D Pharma
      • 6.3.2.1. Company overview
      • 6.3.2.2. Financial performance
      • 6.3.2.3. Service benchmarking
      • 6.3.2.4. Strategic initiatives
    • 6.3.3. Cerbios
      • 6.3.3.1. Company overview
      • 6.3.3.2. Financial performance
      • 6.3.3.3. Service benchmarking
      • 6.3.3.4. Strategic initiatives
    • 6.3.4. Biose Industrie
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Service benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Assembly Biosciences, Inc.
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Service benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. Wacker Chemie AG
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Service benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Quay Pharmaceuticals
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Service benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. NIZO
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Service benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. Lonza
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Service benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. Inpac Probiotics
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Service benchmarking
      • 6.3.10.4. Strategic initiatives